| Recruiting | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults Influenza | Phase 3 | 2026-03-23 |
| Recruiting | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age Epstein-Barr Virus | Phase 1 | 2026-03-17 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age W SARS-CoV-2 | Phase 4 | 2025-11-26 |
| Recruiting | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2025-09-30 |
| Active Not Recruiting | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Respiratory Syncytial Virus | Phase 3 | 2025-08-05 |
| Recruiting | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations COVID-19 | Phase 4 | 2025-07-21 |
| Recruiting | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participa Multiple Sclerosis | Phase 2 | 2025-04-16 |
| Active Not Recruiting | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants Wit Advanced Solid Tumors | Phase 1 | 2025-03-25 |
| Completed | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Va Influenza, SARS-CoV-2 | Phase 2 | 2025-03-07 |
| Completed | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19 COVID-19, Influenza | Phase 3 | 2024-11-18 |
| Active Not Recruiting | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participant Healthy Participants | Phase 1 | 2024-10-31 |
| Completed | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years Healthy Volunteers | Phase 4 | 2024-10-08 |
| Active Not Recruiting | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Preventio Acute Gastroenteritis, Norovirus Acute Gastroenteritis | Phase 3 | 2024-09-24 |
| Completed | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age Seasonal Influenza | Phase 3 | 2024-09-16 |
| Recruiting | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations SARS-CoV-2 | Phase 4 | 2024-09-09 |
| Completed | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 ( Influenza, SARS-CoV-2 | Phase 2 | 2024-07-15 |
| Completed | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults SARS-CoV-2 | Phase 3 | 2024-04-08 |
| Withdrawn | A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria Phenylketonuria | Phase 1 / Phase 2 | 2024-03-29 |
| Completed | Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants | Phase 1 | 2024-02-16 |
| Withdrawn | A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients Cytomegalovirus Infection | Phase 2 | 2024-02-08 |
| Active Not Recruiting | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Va Respiratory Syncytial Virus | Phase 2 | 2023-11-15 |
| Completed | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age Respiratory Syncytial Virus | Phase 2 | 2023-10-24 |
| Completed | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age SARS-CoV-2, Influenza | Phase 3 | 2023-10-19 |
| Active Not Recruiting | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Viru Respiratory Syncytial Virus | Phase 3 | 2023-10-06 |
| Completed | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Vir Respiratory Syncytial Virus | Phase 3 | 2023-09-25 |
| Completed | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to Genital Herpes | Phase 1 / Phase 2 | 2023-09-06 |
| Active Not Recruiting | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovir Norovirus Acute Gastroenteritis | Phase 1 / Phase 2 | 2023-08-25 |
| Completed | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared Smallpox, Mpox | Phase 1 / Phase 2 | 2023-08-15 |
| Withdrawn | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Relapsed or Refractory Multiple Myeloma | Phase 1 | 2023-08-15 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participa Lyme Disease | Phase 1 / Phase 2 | 2023-07-26 |
| Completed | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults Influenza | Phase 1 / Phase 2 | 2023-07-10 |
| Recruiting | A Retrospective Study to Characterize Participants With Propionic Acidemia Propionic Acidemia | — | 2023-06-16 |
| Completed | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healt Influenza | Phase 2 | 2023-05-15 |
| Completed | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Seasonal Influenza | Phase 3 | 2023-04-17 |
| Completed | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults SARS-CoV-2, Influenza | Phase 1 / Phase 2 | 2023-04-14 |
| Completed | Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran SARS-CoV-2 | — | 2023-04-14 |
| Active Not Recruiting | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participant Epstein-Barr Virus Infection | Phase 1 | 2023-04-05 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in All Cytomegalovirus Infection | Phase 2 | 2023-04-05 |
| Completed | A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID- Myocarditis, Pericarditis | — | 2023-03-31 |
| Completed | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent C COVID-19 | Phase 3 | 2023-03-28 |
| Completed | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Seasonal Influenza | Phase 1 / Phase 2 | 2023-03-27 |
| Active Not Recruiting | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEV SARS-CoV-2 | — | 2023-03-10 |
| Completed | An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated COVID-19 | — | 2023-03-08 |
| Completed | Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy Maternal Outcomes, Infant Outcomes, Pregnancy | — | 2023-03-01 |
| Active Not Recruiting | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to < Respiratory Syncytial Virus, Human Metapneumovirus | Phase 1 | 2023-02-15 |
| Active Not Recruiting | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Herpes Zoster | Phase 1 / Phase 2 | 2023-01-23 |
| Completed | A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure Chronic Heart Failure | Phase 1 | 2022-12-05 |
| Completed | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV SARS-CoV-2 | — | 2022-11-15 |
| Completed | Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavi SARS-CoV-2 | — | 2022-11-15 |
| Completed | Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Res SARS-CoV-2 | — | 2022-11-15 |
| Active Not Recruiting | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 Cytomegalovirus | Phase 1 / Phase 2 | 2022-11-07 |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults Influenza | Phase 2 | 2022-11-02 |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RS SARS-CoV-2, Influenza, RSV | Phase 1 | 2022-10-14 |
| Terminated | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine SARS-CoV-2 | Phase 2 | 2022-09-30 |
| Completed | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study Respiratory Syncytial Virus | — | 2022-09-15 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Seasonal Influenza | Phase 3 | 2022-09-14 |
| Recruiting | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1 / Phase 2 | 2022-09-01 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 SARS-CoV-2 | Phase 3 | 2022-06-21 |
| Completed | Use of Wearable Digital Sensors After mRNA Vaccination in Adults Healthy Participants | — | 2022-06-16 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Seasonal Influenza | Phase 3 | 2022-06-06 |
| Active Not Recruiting | A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) Glycogen Storage Disease | Phase 1 / Phase 2 | 2022-06-01 |
| Completed | A Study of Modified mRNA Vaccines in Healthy Adults SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus | Phase 1 | 2022-05-24 |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 7 SARS-CoV-2, Influenza | Phase 1 / Phase 2 | 2022-05-13 |
| Active Not Recruiting | A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVA Myocarditis | — | 2022-04-30 |
| Completed | A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind SARS-CoV-2 | — | 2022-04-11 |
| Completed | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults Seasonal Influenza | Phase 1 / Phase 2 | 2022-04-06 |
| Completed | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age Respiratory Syncytial Virus | Phase 3 | 2022-04-01 |
| Recruiting | An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previou Methylmalonic Acidemia | Phase 1 / Phase 2 | 2022-03-08 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Boo SARS-CoV-2 | Phase 2 / Phase 3 | 2022-02-16 |
| Active Not Recruiting | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents Epstein-Barr Virus Infection | Phase 1 / Phase 2 | 2021-12-28 |
| Completed | Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination Coronavirus Disease (COVID-19) | — | 2021-12-22 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters SARS-CoV-2 | Phase 2 | 2021-12-06 |
| Completed | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) i Respiratory Syncytial Virus | Phase 2 / Phase 3 | 2021-11-17 |
| Recruiting | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled Propionic Acidemia | Phase 1 / Phase 2 | 2021-11-09 |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Cytomegalovirus Infection | Phase 1 | 2021-11-08 |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Hea Cytomegalovirus Infection | Phase 3 | 2021-10-26 |
| Completed | A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults SARS-CoV-2 | — | 2021-09-10 |
| Terminated | Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study SARS-CoV-2 | — | 2021-09-01 |
| Active Not Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolate Methylmalonic Acidemia | Phase 1 / Phase 2 | 2021-08-06 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy A Healthy Volunteers | Phase 1 | 2021-07-28 |
| Completed | Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 SARS-CoV-2 | — | 2021-07-07 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults Seasonal Influenza | Phase 1 / Phase 2 | 2021-07-06 |
| Completed | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vacci Cytomegalovirus Infection | Phase 2 | 2021-06-18 |
| Completed | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas Zika Virus | Phase 2 | 2021-06-07 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants SARS-CoV-2 | Phase 2 / Phase 3 | 2021-05-28 |
| Completed | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transpla SARS-CoV-2 | Phase 3 | 2021-04-16 |
| Recruiting | Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia Propionic Acidemia | Phase 1 / Phase 2 | 2021-04-15 |
| Completed | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Month SARS-CoV-2 | Phase 2 / Phase 3 | 2021-03-15 |
| Completed | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy SARS-CoV-2 | Phase 1 | 2021-03-11 |
| Completed | A Study of the Effectiveness of Moderna COVID-19 Vaccine SARS-CoV-2, COVID-19 | — | 2020-12-18 |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <1 SARS-CoV-2 | Phase 2 / Phase 3 | 2020-12-09 |
| Completed | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults Respiratory Syncytial Virus | Phase 1 | 2020-09-30 |
| Completed | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Olde SARS-CoV-2 | Phase 3 | 2020-07-27 |
| Completed | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vacci SARS-CoV-2 | Phase 2 | 2020-05-29 |
| Completed | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Hea Cytomegalovirus Infection | Phase 2 | 2020-01-09 |
| Completed | Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 Human Metapneumovirus and Human Parainfluenza Infection | Phase 1 | 2019-11-04 |
| Completed | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Sero Zika Virus | Phase 1 | 2019-07-30 |
| Active Not Recruiting | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Pa Melanoma | Phase 2 | 2019-07-18 |
| Withdrawn | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors | Phase 1 / Phase 2 | 2019-05-28 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults Prevention of Chikungunya Virus Infection | Phase 1 | 2019-01-22 |
| Completed | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma | Phase 1 | 2018-11-27 |
| Completed | "The MaP Study": Mapping the Patient Journey in MMA and PA Methylmalonic Acidemia, Propionic Acidemia | — | 2018-03-20 |
| Completed | Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults Human Metapneumovirus and Human Parainfluenza Infection | Phase 1 | 2017-12-04 |
| Completed | Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adul Cytomegalovirus Infection | Phase 1 | 2017-11-13 |
| Terminated | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durva Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer | Phase 1 / Phase 2 | 2017-08-15 |
| Active Not Recruiting | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumo Solid Tumors | Phase 1 | 2017-08-14 |
| Completed | Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants Chikungunya Virus | Phase 1 | 2017-07-19 |
| Completed | Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects Zika Virus | Phase 1 | 2016-12-21 |
| Completed | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects Influenza | Phase 1 | 2016-05-11 |
| Completed | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects Influenza | Phase 1 | 2015-12-01 |